Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia

Neuroscience Letters

Volumn 558, Issue , 2014, Pages 26-30

  Wu, Yijuan ^a,b   Wang, Lijuan ^b   Dai, Chengbo ^b   Ma, Guixian ^b   Zhang, Yuhu ^b   Zhang, Xiong ^b   Wu, Zhuohua ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Matrix metalloproteinase; MCAO; PAF acetylhydrolase; Transient ischemia; Treatment; VEGF

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; NEUROPROTECTIVE AGENT; RECOMBINANT ENZYME; RECOMBINANT PAF AH; TETRAZOLIUM; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SENSORIMOTOR FUNCTION; TRANSIENT ISCHEMIC ATTACK; WESTERN BLOTTING;

MATRIX METALLOPROTEINASE; MCAO; PAF-ACETYLHYDROLASE; TRANSIENT ISCHEMIA; TREATMENT; VEGF;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CEREBRAL INFARCTION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888121221     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.09.005     Document Type: Article

References (34)

1. Alfaro V. Role of histamine and platelet-activating factor in allergic rhinitis. J. Physiol. Biochem. 2004, 60:101-111.
2. Liu N.K., Xu X.M. Phospholipase A2 and its molecular mechanism after spinal cord injury. Mol. Neurobiol. 2010, 41:197-205.
3. Mukai K., Obata K., Tsujimura Y., Karasuyama H. New insights into the roles for basophils in acute and chronic allergy. Allergol. Int. 2009, 58:9-11.
4. Faden A.I., Tzendzalian P.A. Platelet-activating factor antagonists limit glycine changes and behavioral deficits after brain trauma. Am. J. Physiol. 1992, 263:R909-R914.
5. Farbiszewski R., Dudek H., Skrzydlewska E., Lewko J. The role of platelet activating factor (PAF) in physiology and pathology of the central nervous system. Neurol. Neurochir. Pol. 2002, 36:801-808.
6. Uchiyama S., Nakamura T., Yamazaki M., Kimura Y., Iwata M. New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc. Dis. Suppl. 2006, 1N:7-16.
7. Umemura K., Kato I., Hirashima Y., Ishii Y., Inoue T., Aoki J., Kono N., Oya T., Hayashi N., Hamada H., Endo S., Oda M., Arai H., Kinouchi H., Hiraga K. Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke 2007, 38:1063-1068.
8. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:3983-3994.
9. Tai S.H., Chen H.Y., Lee E.J., Chen T.Y., Lin H.W., Hung Y.C., Huang S.Y., Chen Y.H., Lee W.T., Wu T.S. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia. J. Pineal Res. 2010, 49:332-341.
10. Blanco M., Rodríguez-Yáñez M., Sobrino T., Leira R., Castillo J. Platelets, inflammation, and atherothrombotic neurovascular disease: the role of endothelial dysfunction. Cerebrovasc. Dis. 2005, 20:32-39.
11. Gasche Y., Soccal P.M., Kanemitsu M., Copin J.C. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front. Biosci. 2006, 11:1289-1301.
12. Cesca F., Yabe A., Spencer-Dene B., Scholz-Starke J., Medrihan L., Maden C.H., Gerhardt H., Orriss I.R., Baldelli P., Al-Qatari M., Koltzenburg M., Adams R.H., Benfenati F., Schiavo G. Kidins220/ARMS mediates the integration of the neurotrophin and VEGF pathways in the vascular and nervous systems. Cell Death Differ. 2012, 19:194-208.
13. Millán M., Arenillas J. Gene expression in cerebral ischemia: a new approach for neuroprotection. Cerebrovasc. Dis. 2006, 2(Suppl. 21):30-37.
14. Liu Y.G., Zhou Y., Hu X., Fu J.J., Pan Y., Chu T.W. Effect of vascular endothelial growth factor 121 adenovirus transduction in rabbit model of femur head necrosis. J. Trauma 2011, 70:1529-8809.
15. Rodríguez-González R., Hurtado O., Sobrino T., Castillo J. Neuroplasticity and cellular therapy in cerebral infarction. Cerebrovasc. Dis. 2007, 24:167-180.
16. Su H., Yang G.Y. Treatment of focal brain ischemia with viral vector-mediated gene transfer. Methods Mol. Biol. 2011, 686:429-446.
17. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
18. Sen S., Hinderliter A., Sen P.K., Simmons J., Beck J., Offenbacher S., Ohman E.M., Oppenheimer S.M. Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. Circulation 2007, 116:928-935.
19. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1998, 20:84-91.
20. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
21. Belayev L., Eady T.N., Khoutorova L., Atkins K.D., Obenaus A., Cordoba M., Vaquero J.J., Alvarez-Builla J., Bazan N.G. Superior neuroprotective efficacy of LAU-0901, a novel platelet-activating factor antagonist, in experimental stroke. Transl. Stroke Res. 2012, 3:154-163.
22. Maerz S., Liu C.H., Guo W., Zhu Y.Z. Anti-ischemic effects of bilobalide on neonatal rat cardiomyocytes and the involvement of the platelet-activating factor receptor. Biosci. Rep. 2011, 31(Pt 5):439-447.
23. Koumura A., Hamanaka J., Kawasaki K., Tsuruma K., Shimazawa M., Hozumi I., Inuzuka T., Hara H. Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. J. Pharmacol. Exp. 2011, 338:337-344.
24. Belayev L., Khoutorova L., Atkins K., Cherqui A., Alvarez-Builla J., Bazan N.G. LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat. Brain Res. 2009, 1253:184-190.
25. Ko H.M., Kang J.H., Jung B., Kim H.A., Park S.J., Kim K.J., Kang Y.R., Lee H.K., Im S.Y. Critical role for matrix metalloproteinase-9 in platelet-activating factor-induced experimental tumor metastasis. Int. J. Cancer 2007, 120:1277-1283.
26. Fatar M., Stroick M., Griebe M., Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc. Dis. 2005, 20:141-151.
27. Melnikova V.O., Villares G.J., Bar-Eli M. Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Micorenviron. 2008, 1:103-111.
28. Góra-Kupilas K., Jośko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 2005, 43:31-39.
29. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005, 14:207-221.
30. Ortuzar N., Argandona E.G., Bengoetxea H., Lafuente J.V. Combination of intracortically administered VEGF and environmental enrichment enhances brain protection in developing rats. J. Neural Transm. 2011, 118:135-144.
31. Yang Z.J., Bao W.L., Qiu M.H., Zhang L.M., Lu S.D., Huang Y.L., Sun F.Y. Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia. J. Neurosci. Res. 2002, 70:140-149.
32. Zheng X.R., Zhang S.S., Yin F., Yang Y.J., Zhong L., Wang X., Yu X.H. Adenovirus-mediated vascular endothelial growth factor165 gene therapy in treatment of hypoxic-ischemic brain damage: experiment with rats. Zhonghua Yi Xue Za Zhi 2009, 89:128-132.
33. Laudenbach V., Fontaine R.H., Medja F., Carmeliet P., Hicklin D.J., Gallego J., Leroux P., Marret S., Gressens P. Neonatal hypoxic preconditioning involves vascular endothelial growth factor. Neurobiol. Dis. 2007, 26:243-252.
34. Wang Q., Zhang Q.G., Wu D.N., Yin X.H., Zhang G.Y. Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway. Acta Pharmacol. Sin. 2007, 28:19-27.